

## AMENDMENTS TO THE CLAIMS

1. (Original) A minimally invasive therapeutic agent delivery system for treating macular degeneration, said system comprising:
  - a reservoir comprising a therapeutic agent for dissolving lipid waste deposits in at least Bruch's membrane;
  - an elongate probe, wherein said probe:
    - defines a passage therein;
    - is configured to conform at least in part to the curvature of the eye;
    - has a proximal probe end and a distal probe end including a distal probe opening;
  - a therapeutic agent delivery apparatus, said therapeutic agent delivery apparatus being:
    - fluidly connected to said reservoir;
    - configured to be disposed within said passage; and
    - movable between a retracted inoperative position within said probe and an extended operational position when said distal probe end is disposed adjacent the sclera of an eye suffering from macular degenerationwherein movement of said delivery apparatus from the inactive to the operational position enables the therapeutic agents to be dispensed from said reservoir through said distal probe opening into the eye for the treatment of macular degeneration.
2. (Original) The system of claim 1 and further including a handle attached to said probe proximal end.
3. (Original) The system of claim 1 and further including a handle attached to said probe proximal end, wherein said reservoir is attached to said handle.

4. (Original) The system of claim 1 wherein said therapeutic agent delivery apparatus comprises an elongate needle.
5. (Original) The system of claim 4 wherein said probe distal end includes an eye-surface engaging surface configured to conform to the surface of the eye.
6. (Original) The system of claim 5 wherein said probe passage includes a portion conforming to the surface of the eye and a portion that angles toward the eye such that said distal probe opening is in said eye-surface engaging surface.
7. (Original) The system of claim 5 wherein said passage bends said needle when said needle is moved from its retracted to its extended position.
8. (Original) The system of claim 1 wherein said probe includes a probe positioning portion at said distal probe end for engaging the optic nerve and positioning said distal probe opening relative to the fovea of the eye.
9. (Original) The system of claim 1 wherein said therapeutic agent delivery apparatus comprises an array of micro-needles.
10. (Original) The system of claim 9 wherein said probe houses a spring within said passage, said spring being provided for moving said array from its inoperative position to its operative position.
11. (Original) The system of claim 9 wherein said array is movable between retracted and extended positions by a spring.
12. (Original) The system of claim 1 wherein said therapeutic agent delivery apparatus comprises a porous pad.

13. (Original) The system of claim 12 wherein said pad is movable between operative and inoperative positions by a spring.

14. (Original) The system of claim 1 wherein said therapeutic agent delivery apparatus comprises a plurality of porous pads and at least one conductive pad, said porous pads being electrically connected to the negative electrode of a power source and said conductive pad being electrically connected to the positive electrode of a power source, said electrical connections being provided to enhance diffusion of the therapeutic agent into the eye.

Claims 15-26 (Canceled)